CLONIDINE Drug Patent Profile
✉ Email this page to a colleague
When do Clonidine patents expire, and when can generic versions of Clonidine launch?
Clonidine is a drug marketed by Tris Pharma Inc, Actavis Labs Ut Inc, Aveva, Dr Reddys Labs Sa, Mylan Technologies, Am Regent, Fresenius Kabi Usa, Hikma Farmaceutica, Xgen Pharms, Zydus Pharms, Actavis Elizabeth, Ajanta Pharma Ltd, Amneal Pharms Ny, Anchen Pharms, Bluepharma Industria, Chartwell Rx, Jubilant Generics, Novast Labs, Xiamen Lp Pharm Co, Alembic Pharms Ltd, Am Therap, Aurobindo Pharma Ltd, Chartwell Molecules, Duramed Pharms Barr, Impax Labs, Interpharm, Par Pharm, Prinston Inc, Rising, Sun Pharm Inds Inc, Teva, Unichem, Url Labs, Warner Chilcott, Watson Labs, and Yung Shin Pharm. and is included in sixty-two NDAs.
The generic ingredient in CLONIDINE is chlorthalidone; clonidine hydrochloride. There are twenty-one drug master file entries for this compound. Additional details are available on the chlorthalidone; clonidine hydrochloride profile page.
Summary for CLONIDINE
| US Patents: | 0 |
| Applicants: | 36 |
| NDAs: | 62 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 71 |
| Clinical Trials: | 372 |
| Patent Applications: | 5,913 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CLONIDINE |
| Drug Sales Revenues: | Drug sales revenues for CLONIDINE |
| What excipients (inactive ingredients) are in CLONIDINE? | CLONIDINE excipients list |
| DailyMed Link: | CLONIDINE at DailyMed |
Recent Clinical Trials for CLONIDINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute, Egypt | N/A |
| Sollis Therapeutics, Inc. | Phase 3 |
| Loyola University | Phase 4 |
Pharmacology for CLONIDINE
| Drug Class | Central alpha-2 Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha2-Agonists |
Medical Subject Heading (MeSH) Categories for CLONIDINE
Anatomical Therapeutic Chemical (ATC) Classes for CLONIDINE
US Patents and Regulatory Information for CLONIDINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rising | CLONIDINE HYDROCHLORIDE | clonidine hydrochloride | TABLET;ORAL | 070317-001 | Jun 9, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Actavis Elizabeth | CLONIDINE HYDROCHLORIDE | clonidine hydrochloride | TABLET;ORAL | 070975-001 | Dec 16, 1986 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Anchen Pharms | CLONIDINE HYDROCHLORIDE | clonidine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 202983-002 | Apr 2, 2014 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
